Outlook Therapeutics (OTLK) Stock Forecast, Price Target & Predictions
OTLK Stock Forecast
Outlook Therapeutics stock forecast is as follows: a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
OTLK Analyst Ratings
According to 5 Wall Street analysts, Outlook Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for OTLK stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 17, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Mar 27, 2024 | BTIG | - | Buy | Upgrade |
| Jan 25, 2024 | Guggenheim | - | Buy | Upgrade |
| Jan 25, 2024 | Brookline Capital | - | Buy | Upgrade |
| Dec 29, 2023 | Ascendiant | Buy | Buy | Hold |
| Nov 03, 2023 | H.C. Wainwright | - | Buy | Upgrade |
Outlook Therapeutics's last stock rating was published by H.C. Wainwright on May 17, 2024. The company gave OTLK a "Buy" rating, the same as its previous rate.
Outlook Therapeutics Financial Forecast
Outlook Therapeutics Revenue Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 23 | Sep 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Jun 17 | Dec 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $5.85M | $583.85K | $641.14K | $771.89K | $303.14K | $303.14K |
| Avg Forecast | $6.25M | $2.25M | $702.60K | $200.00K | $237.67K | - | $2.49M | $300.00K | $325.00K | $325.00K | $162.50K | $216.67K | $162.50K | $333.33K | $637.50K | $683.33K | $750.00K | $553.44K | $872.73K | $235.54K |
| High Forecast | $6.25M | $2.25M | $702.60K | $200.00K | $237.67K | - | $2.49M | $300.00K | $325.00K | $325.00K | $162.50K | $216.67K | $162.50K | $333.33K | $637.50K | $683.33K | $750.00K | $664.12K | $1.05M | $282.65K |
| Low Forecast | $6.25M | $2.25M | $702.60K | $200.00K | $237.67K | - | $2.49M | $300.00K | $325.00K | $325.00K | $162.50K | $216.67K | $162.50K | $333.33K | $637.50K | $683.33K | $750.00K | $442.75K | $698.18K | $188.43K |
| # Analysts | 1 | 1 | 1 | 4 | 1 | - | 4 | 2 | 2 | 2 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 13 | 16 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.18% | 0.85% | 0.85% | 1.39% | 0.35% | 1.29% |
Outlook Therapeutics's average Quarter revenue forecast for Dec 19 based on 4 analysts is $333.33K, with a low forecast of $333.33K, and a high forecast of $333.33K. OTLK's average Quarter revenue forecast represents a -94.31% decrease compared to the company's last Quarter revenue of $5.85M (Sep 19).
Outlook Therapeutics EBITDA Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 23 | Sep 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Jun 17 | Dec 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 1 | - | 4 | 2 | 2 | 2 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 13 | 16 |
| EBITDA | - | - | - | - | - | - | $-56.84T | $-52.18M | $-11.89M | $-12.77M | $-9.82M | $-5.72M | $-4.83M | $-15.83M | $-11.63M | $-3.30M | $-8.37M | $-5.89M | $-3.02M | $-18.04M |
| Avg Forecast | $3.75M | $1.35M | $421.56K | $120.00K | $142.60K | - | $1.49M | $180.00K | $195.00K | $-10.98M | $97.50K | $130.00K | $-2.71M | $200.00K | $382.50K | $410.00K | $-9.39M | $-3.58M | $-4.50M | $-12.86M |
| High Forecast | $3.75M | $1.35M | $421.56K | $120.00K | $142.60K | - | $1.49M | $180.00K | $195.00K | $-8.78M | $97.50K | $130.00K | $-2.17M | $200.00K | $382.50K | $410.00K | $-7.51M | $-2.87M | $-3.60M | $-10.29M |
| Low Forecast | $3.75M | $1.35M | $421.56K | $120.00K | $142.60K | - | $1.49M | $180.00K | $195.00K | $-13.17M | $97.50K | $130.00K | $-3.25M | $200.00K | $382.50K | $410.00K | $-11.27M | $-4.30M | $-5.40M | $-15.43M |
| Surprise % | - | - | - | - | - | - | -38087260.87% | -289.87% | -60.98% | 1.16% | -100.75% | -44.00% | 1.78% | -79.15% | -30.41% | -8.06% | 0.89% | 1.64% | 0.67% | 1.40% |
undefined analysts predict OTLK's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Outlook Therapeutics's previous annual EBITDA (undefined) of $NaN.
Outlook Therapeutics Net Income Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 23 | Sep 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Jun 17 | Dec 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 1 | - | 4 | 2 | 2 | 2 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 13 | 16 |
| Net Income | - | - | - | - | - | - | $-58.98T | $-53.16M | $-12.20M | $-13.11M | $-9.92M | $-3.01M | $-5.70M | $-16.60M | $-10.10M | $-4.44M | $-10.24M | $-7.54M | $-5.33M | $-19.10M |
| Avg Forecast | $-10.46M | $-14.12M | $-18.05M | $-22.57M | $-20.48M | $-26.31M | $-29.30M | $-32.27M | $-35.67M | $-11.47M | $-47.90M | $-48.41M | $-2.51M | $-112.10M | $-157.95M | $-185.13M | $-11.49M | $-4.59M | $-7.94M | $-13.62M |
| High Forecast | $-10.46M | $-14.12M | $-18.05M | $-22.57M | $-18.76M | $-26.31M | $-24.41M | $-32.27M | $-35.67M | $-9.17M | $-47.90M | $-48.41M | $-2.01M | $-112.10M | $-157.95M | $-185.13M | $-9.19M | $-3.67M | $-6.35M | $-10.89M |
| Low Forecast | $-10.46M | $-14.12M | $-18.05M | $-22.57M | $-21.97M | $-26.31M | $-39.06M | $-32.27M | $-35.67M | $-13.76M | $-47.90M | $-48.41M | $-3.01M | $-112.10M | $-157.95M | $-185.13M | $-13.78M | $-5.51M | $-9.53M | $-16.34M |
| Surprise % | - | - | - | - | - | - | 2013202.69% | 1.65% | 0.34% | 1.14% | 0.21% | 0.06% | 2.27% | 0.15% | 0.06% | 0.02% | 0.89% | 1.64% | 0.67% | 1.40% |
Outlook Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. OTLK's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Outlook Therapeutics SG&A Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 23 | Sep 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Jun 17 | Dec 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 1 | - | 4 | 2 | 2 | 2 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 13 | 16 |
| SG&A | - | - | - | - | - | - | $26.67T | $12.77M | $2.93M | $4.10M | $2.39M | $3.29M | $1.96M | $2.34M | $2.78M | $1.83M | $1.85M | $2.45M | $3.50M | $4.89M |
| Avg Forecast | $5.84M | $2.10M | $657.35K | $187.12K | $222.36K | - | $2.33M | $280.68K | $304.07K | $304.07K | $152.03K | $202.71K | $152.03K | $311.86K | $596.44K | $639.32K | $701.70K | $517.79K | $816.52K | $220.37K |
| High Forecast | $5.84M | $2.10M | $657.35K | $187.12K | $222.36K | - | $2.33M | $280.68K | $304.07K | $304.07K | $152.03K | $202.71K | $152.03K | $311.86K | $596.44K | $639.32K | $701.70K | $621.35K | $979.82K | $264.44K |
| Low Forecast | $5.84M | $2.10M | $657.35K | $187.12K | $222.36K | - | $2.33M | $280.68K | $304.07K | $304.07K | $152.03K | $202.71K | $152.03K | $311.86K | $596.44K | $639.32K | $701.70K | $414.23K | $653.21K | $176.30K |
| Surprise % | - | - | - | - | - | - | 11462795.53% | 45.49% | 9.64% | 13.47% | 15.72% | 16.21% | 12.87% | 7.49% | 4.66% | 2.87% | 2.64% | 4.72% | 4.29% | 22.18% |
Outlook Therapeutics's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to OTLK last annual SG&A of $26.67T (Sep 23).
Outlook Therapeutics EPS Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 23 | Sep 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Jun 17 | Dec 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 1 | - | 4 | 2 | 2 | 2 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 13 | 16 |
| EPS | - | - | - | - | - | - | $-0.24 | $-0.32 | $-0.07 | $-0.09 | $-0.11 | $-0.03 | $-0.12 | $-0.62 | $-0.34 | $-0.20 | $-0.98 | $-2.64 | $-1.76 | $-6.56 |
| Avg Forecast | $-0.41 | $-0.55 | $-0.71 | $-0.89 | $-0.80 | $-1.03 | $-1.15 | $-1.27 | $-1.40 | $-1.93 | $-1.88 | $-1.90 | $-2.88 | $-4.40 | $-6.20 | $-7.27 | $-13.20 | $-1.12 | $-7.63 | $-0.31 |
| High Forecast | $-0.41 | $-0.55 | $-0.71 | $-0.89 | $-0.74 | $-1.03 | $-0.96 | $-1.27 | $-1.40 | $-1.93 | $-1.88 | $-1.90 | $-2.88 | $-4.40 | $-6.20 | $-7.27 | $-13.20 | $-0.90 | $-6.11 | $-0.25 |
| Low Forecast | $-0.41 | $-0.55 | $-0.71 | $-0.89 | $-0.86 | $-1.03 | $-1.53 | $-1.27 | $-1.40 | $-1.93 | $-1.88 | $-1.90 | $-2.88 | $-4.40 | $-6.20 | $-7.27 | $-13.20 | $-1.34 | $-9.16 | $-0.37 |
| Surprise % | - | - | - | - | - | - | 0.21% | 0.25% | 0.05% | 0.05% | 0.06% | 0.02% | 0.04% | 0.14% | 0.05% | 0.03% | 0.07% | 2.36% | 0.23% | 21.16% |
According to undefined Wall Street analysts, Outlook Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to OTLK previous annual EPS of $NaN (undefined).
Outlook Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.37 | $3.67 | 891.89% | Buy |
| RVPH | Reviva Pharmaceuticals | $1.26 | $10.00 | 693.65% | Buy |
| CKPT | Checkpoint Therapeutics | $3.38 | $20.00 | 491.72% | Buy |
| HRTX | Heron Therapeutics | $1.19 | $7.00 | 488.24% | Buy |
| KOD | Kodiak Sciences | $5.64 | $31.60 | 460.28% | Buy |
| SLS | SELLAS Life Sciences Group | $1.29 | $7.00 | 442.64% | Buy |
| INZY | Inozyme Pharma | $2.81 | $14.67 | 422.06% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.52 | $38.80 | 186.98% | Buy |
| EYPT | EyePoint Pharmaceuticals | $9.21 | $26.00 | 182.30% | Buy |
| TERN | Terns Pharmaceuticals | $5.91 | $14.25 | 141.12% | Buy |
| OTLK | Outlook Therapeutics | $5.23 | $10.00 | 91.20% | Buy |
| CDTX | Cidara Therapeutics | $15.63 | $24.00 | 53.55% | Buy |
| HOOK | HOOKIPA Pharma | $2.79 | $3.00 | 7.53% | Buy |